Bluejay Therapeutics is a technology company.
Bluejay Therapeutics has raised $221.0M across 2 funding rounds.
Bluejay Therapeutics has raised $221.0M in total across 2 funding rounds.
Bluejay Therapeutics is a private biopharmaceutical company developing curative treatments for viral infections and liver diseases.[1] Led by founder and CEO Dr. Keting Chu, it focuses on innovative therapies in these high-unmet-need areas, drawing on Chu's extensive experience in biotech R&D, executive leadership, and venture investing.[1]
The company targets patients with chronic viral infections and liver conditions, addressing challenges like limited curative options through advanced therapeutic development. Its growth is propelled by Chu's track record of successful investments and leadership in companies that achieved FDA approvals, acquisitions, and breakthrough designations.[1]
Bluejay Therapeutics was founded by Dr. Keting Chu, an accomplished biotech executive, entrepreneur, and investor.[1] Chu's career spans leadership roles at major firms like Chiron Corporation (Head of Immunotherapy and Antibody Therapeutics), Five Prime Therapeutics (VP of Biology and Head of R&D), Mission Therapeutics (CEO), and DigitAB, Inc. and BioCubed Corporation (Co-Founder, President, and CEO).[1]
Her venture experience includes VP of Research at The Leukemia and Lymphoma Society's Therapy Acceleration Program, where she drove investments in high-impact oncology firms like Celator (acquired for $1.5B), Kite Pharma (acquired for $12B), and Stemline (acquired for $677M), several earning FDA Breakthrough designations and approvals.[1] This expertise likely sparked Bluejay's formation to tackle viral and liver diseases, building on her history of advancing therapies from discovery to clinical stages.[1]
Bluejay stands out in biopharma through:
Bluejay rides the wave of precision medicine and curative therapies for infectious diseases and hepatology, amplified by post-pandemic urgency for viral treatments and rising liver disease prevalence from metabolic factors.[1] Timing aligns with advances in biologics and gene therapies, where Chu's antibody and immunotherapy background positions Bluejay to capitalize on modalities she pioneered.[1]
Market forces like FDA fast-track incentives for breakthroughs favor Bluejay, echoing Chu's prior successes amid growing venture interest in high-impact biopharma. It influences the ecosystem by modeling efficient, investor-driven paths to cures, potentially accelerating startups in viral/liver spaces through Chu's network.[1]
Bluejay is poised for clinical milestones, likely pursuing proof-of-concept trials in viral infections or liver diseases, leveraging Chu's fast-track history.[1] Trends like AI-aided drug discovery and mRNA platforms for antivirals could accelerate its pipeline, while partnerships (drawing from her venture ties) fuel growth.[1]
Its influence may expand via acquisitions or IPOs, akin to Chu's past exits, solidifying Bluejay as a curative therapy leader—illuminating paths where few have succeeded, as its motto promises: "Expect More."[1]
Bluejay Therapeutics has raised $221.0M in total across 2 funding rounds.
Bluejay Therapeutics's investors include Eric Shiozaki, Digitalis Ventures, Frazier Healthcare Partners, RiverVest, Westlake Village BioPartners.
Bluejay Therapeutics has raised $221.0M across 2 funding rounds. Most recently, it raised $180.0M Series C in May 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2024 | $180.0M Series C | Eric Shiozaki, Digitalis Ventures, Frazier Healthcare Partners, RiverVest, Westlake Village BioPartners | |
| Aug 1, 2022 | $41.0M Series B | Digitalis Ventures, RiverVest |